MX2019004621A - Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. - Google Patents

Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.

Info

Publication number
MX2019004621A
MX2019004621A MX2019004621A MX2019004621A MX2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A
Authority
MX
Mexico
Prior art keywords
bispecific antibody
multiple myeloma
combined use
treating multiple
antibody against
Prior art date
Application number
MX2019004621A
Other languages
English (en)
Inventor
Strein Klaus
Diem VU Minh
David Lourenço Paiva Bruno
Fernando San Miguel Izquierdo Jesús
Original Assignee
Engmab Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab Sarl filed Critical Engmab Sarl
Publication of MX2019004621A publication Critical patent/MX2019004621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invención hace referencia a un anticuerpo biespecifico que se une de forma específica al antígeno de maduración de linfocitos B (BCMA) humano y al CD3e (CD3) humano, junto con un fármaco inmunoterapeutico para uso combinado en el tratamiento del mieloma múltiple.
MX2019004621A 2016-11-02 2017-11-02 Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. MX2019004621A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16196874 2016-11-02
PCT/EP2017/078109 WO2018083204A1 (en) 2016-11-02 2017-11-02 Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

Publications (1)

Publication Number Publication Date
MX2019004621A true MX2019004621A (es) 2019-11-28

Family

ID=57226831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004621A MX2019004621A (es) 2016-11-02 2017-11-02 Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.

Country Status (14)

Country Link
US (3) US11124577B2 (es)
EP (2) EP3535295A1 (es)
JP (1) JP7267914B2 (es)
KR (1) KR20190086477A (es)
CN (1) CN110167964B (es)
AU (1) AU2017353427A1 (es)
BR (1) BR112019008426A2 (es)
CA (1) CA3041183A1 (es)
CL (1) CL2019001198A1 (es)
EA (1) EA201990787A1 (es)
IL (1) IL266424B2 (es)
MX (1) MX2019004621A (es)
SG (1) SG11201903359RA (es)
WO (1) WO2018083204A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
DK3411402T3 (da) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
MX2020003856A (es) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc Proteinas de union a antigenos de maduracion de celulas b.
CN112119099A (zh) * 2018-03-02 2020-12-22 Cdr-生物科技股份有限公司 三特异性抗原结合蛋白
AU2019243665B2 (en) 2018-03-30 2023-06-01 Merus N.V. Multivalent antibody
JOP20200292A1 (ar) * 2018-05-16 2020-11-15 Stichting Vumc Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
KR102597053B1 (ko) * 2018-06-26 2023-11-02 에이비엘바이오 주식회사 항-bcma 항체 및 그 용도
EP3823664A1 (en) * 2018-07-19 2021-05-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
AU2019351811A1 (en) * 2018-10-01 2021-05-06 Celgene Corporation Combination therapy for the treatment of cancer
WO2020089437A1 (en) * 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
MX2021011141A (es) 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
WO2020219978A1 (en) * 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
AU2020307471A1 (en) * 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
IL292704A (en) * 2019-11-05 2022-07-01 Bristol Myers Squibb Co Methods of treatment with antibodies against bcma and cd3
EP4054716A1 (en) * 2019-11-05 2022-09-14 F. Hoffmann-La Roche AG Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide
CA3160352A1 (en) * 2019-12-06 2021-06-10 Israel Lowy Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
US20210403587A1 (en) * 2020-04-29 2021-12-30 Teneobio, Inc. Methods of treating multiple myeloma
WO2021228783A1 (en) * 2020-05-11 2021-11-18 Janssen Pharmaceutica Nv Methods for treating multiple myeloma
JP2023524854A (ja) * 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用
EP4153317A1 (en) * 2020-05-19 2023-03-29 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
AU2021339096A1 (en) * 2020-09-14 2023-04-06 Pfizer Inc. Methods, therapies and uses for treating cancer
IL301037A (en) 2020-09-18 2023-05-01 Regeneron Pharma Antigen binding molecules that bind CD38 and/or CD28 and uses thereof
CN112159476B (zh) * 2020-10-10 2022-08-02 中国药科大学 一种用于多发性骨髓瘤的双特异性抗体及其应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
TW202304963A (zh) 2021-04-15 2023-02-01 大陸商正大天晴藥業集團股份有限公司 標靶bcma的多特異性抗體
WO2023081705A1 (en) * 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
WO2023213998A1 (en) 2022-05-06 2023-11-09 Ichnos Sciences SA Cd3/bcma/cd38 trispecific antibodies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CN1183802A (zh) 1994-12-30 1998-06-03 行星生物技术有限公司 在植物中生产含有保护性蛋白质的免疫球蛋白的方法和应用
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DK1642972T3 (da) 1999-01-07 2010-05-10 Zymogenetics Inc Terapeutisk anvendelse af BR43X2 opløselige receptorer
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
EP1314741B1 (en) 2001-11-14 2007-03-07 Affimed Therapeutics AG Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
PL224786B1 (pl) 2003-01-22 2017-01-31 Glycart Biotechnology Ag Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
US20050033031A1 (en) 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
ME03528B (me) 2005-03-23 2020-04-20 Genmab As Antitijela protiv cd38 za liječenje multiplog mijeloma
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
AU2006281980A1 (en) 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
NO345919B1 (no) 2005-08-26 2021-10-18 Roche Glycart Ag Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
MX2008013057A (es) 2006-04-14 2009-04-07 Trubion Pharmaceuticals Inc Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
TR201816277T4 (tr) 2007-04-03 2018-11-21 Amgen Res Munich Gmbh Çapraz-tür-spesifik bağlama alanı.
ES2695047T3 (es) 2007-04-03 2018-12-28 Amgen Research (Munich) Gmbh Dominio de unión específico entre especies
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AU2009204974A1 (en) 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Afucosylated antibodies against CCR5 and their use
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
NO2842575T3 (es) 2008-03-18 2018-02-24
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
PT2352763E (pt) 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2010037838A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2373687B1 (en) 2008-12-03 2016-10-26 Genmab A/S Igg4 antibody variants having modifications in the constant region
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
GB0914330D0 (en) * 2009-08-17 2009-09-30 Univ Dublin City A method of predicting response to thalidomide in multiple myeloma patients
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
RU2595839C2 (ru) * 2010-09-27 2016-08-27 МорфоСис АГ Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
DK3415531T3 (da) 2011-05-27 2023-09-18 Glaxo Group Ltd Bcma (cd269/tnfrsf17)-bindende proteiner
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9486547B2 (en) 2012-11-05 2016-11-08 Morphosys Ag Radiolabelled antibody and uses thereof
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP2017504601A (ja) 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
MY179611A (en) * 2014-08-04 2020-11-11 Hoffmann La Roche Bispecific t cell activating antigen binding molecules
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EA201790543A1 (ru) 2014-09-08 2017-07-31 Селджин Корпорейшн Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CA2992797A1 (en) * 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma

Also Published As

Publication number Publication date
US20190263920A1 (en) 2019-08-29
CL2019001198A1 (es) 2019-07-05
US11124577B2 (en) 2021-09-21
IL266424B1 (en) 2023-05-01
KR20190086477A (ko) 2019-07-22
CA3041183A1 (en) 2018-05-11
CN110167964A (zh) 2019-08-23
EP4295918A2 (en) 2023-12-27
AU2017353427A1 (en) 2019-05-16
US20220017631A1 (en) 2022-01-20
IL266424A (en) 2019-06-30
BR112019008426A2 (pt) 2019-09-03
EP4295918A3 (en) 2024-03-20
EA201990787A1 (ru) 2019-12-30
EP3535295A1 (en) 2019-09-11
JP2020500181A (ja) 2020-01-09
SG11201903359RA (en) 2019-05-30
WO2018083204A1 (en) 2018-05-11
JP7267914B2 (ja) 2023-05-02
US20220002427A1 (en) 2022-01-06
IL266424B2 (en) 2023-09-01
CN110167964B (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
ZA201901066B (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
HUS2300011I1 (hu) Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
SG11202011306TA (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
HK1249525A1 (zh) 一種結合dll3和cd3的雙特異性抗體構建
IL259082A (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
HK1249523A1 (zh) 一種結合和egfrviii和cd3的雙特異性抗體構建物
RS60030B1 (sr) Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
MX2016000272A (es) Construcciones de unión a los antígenos cd19 y cd3 biespecificos.
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof